UTMD
UTAH MEDICAL PRODUCTS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $66.8K at an average $66.75. No open-market sales. Price is 8% above their cost.
- InstitutionsMIXED
Q3 2026: 8 added (0 new), 10 trimmed or exited.
- Short sellersSTEADY
Short interest +7.9% to 151.3K shares. 3.9 days to cover, ≈4.8% of shares.
- TrendDOWNTREND
1% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $5.7M |
| Bank of New York Mellon Corp | ADD | $3.5M |
| MORGAN STANLEY | TRIM | $3.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $1.8M |
| Empowered Funds, LLC | DOUBLED | $501.2K |
| UBS Group AG | NEAR_EXIT | $161.9K |
| BARCLAYS PLC | ADD | $96.3K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $50.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
CORNWELL KEVIN L Chairman, CEO Oct 29, 2026 | BUY | $66.8K |
RICHINS PAUL O Director Jun 29, 2026 | GIFT | $11.0K |
Koopman Brian Principal Financial Officer May 28, 2026 | GIFT | $3.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 1 bullish · 2 bearish · 3 mixed · 5 neutral- NEUTRAL 8-KNov 3, 2026
Utah Medical Products announced a 1.6% increase in its regular quarterly cash dividend to $0.315…
The dividend increase is small and routine. Monitor the next quarterly earnings filing for revenue and earnings trends, which are the primary drivers of UTMD's valuation.
- NEUTRAL INSIDER-BUYOct 29, 2026
UTMD Chairman and CEO Kevin Cornwell made an open-market purchase of 1,000 shares for $67K, his…
The CEO's purchase is small relative to market cap and does not offset the ongoing revenue decline. Monitor Q4 2026 results for evidence that the Orion Medical acquisition and new China distributor…
- NEUTRAL SC TO-I/AOct 29, 2026
Utah Medical Products completed its issuer tender offer, purchasing 327,740 shares at $75.00 per…
The undersubscription (50% of max) suggests either the $75 price was not compelling enough for many holders or limited float was available. Monitor the next 10-Q for cash balance and any further…
- MIXED 8-KOct 22, 2026
UTMD reported Q3 2026 revenue of $8.6M (-12.1% YoY) and GAAP EPS of $0.876 (+6.8% YoY). While…
The Q3 beat on EPS and OI is driven by one-time cost savings (lower litigation, completed IIA amortization) rather than revenue recovery. The key catalyst to watch is whether the new China…
All UTMD filing & press-release reports (11)
- 8-K reportNov 3, 2026
- INSIDER-BUY reportOct 29, 2026
- SC TO-I/A reportOct 29, 2026
- 8-K reportOct 22, 2026
- SC TO-I/A reportOct 5, 2026
- SC TO-C reportSep 25, 2026
- SC TO-C reportSep 24, 2026
- SC TO-I reportSep 23, 2026
- 8-K reportAug 31, 2026
- 8-K reportJul 23, 2026
- 8-K reportApr 23, 2026